Michael Schmidt
Company: Alloy Therapeutics
Job title: Chief Scientific Officer
Seminars:
Accelerating TCE & TCRm Discovery with Diverse & Optimized CD3 Binders 10:30 am
Diverse and optimized CD3 antibodies are critical to unlocking the full potential of TCE and TCRm therapies CD3 affinity, epitope, and signaling strength can be tuned to match the therapeutic application, enabling the development of safer, more effective therapeuticsRead more
day: Day 1